This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Borden, E. C. Articles by Voelkel, J. G. Search for Related Content PubMed PubMed Citation Articles by Borden, E. C. Articles by Voelkel, J. G.

Comparative Antiproliferative Activity in Vitro of Natural Interferons and ß for Diploid and Transformed Human Cells¹

Departments of Human Oncology [E. C. B., T. F. H., J. G. V.], Medicine [E. C. B., T. F. H.], and Biostatistics [J. G. V.], The University of Wisconsin, Madison, Wisconsin 53792

The relative antiproliferative activity of natural interferons and ß was compared in 43 in vitro assays of 25 human cell lines or strains. After 120 hr of continuous exposure to 100 units/ml, interferon ß produced >20% growth inhibition in 22 cells (88%), and interferon produced 20% growth inhibition in 9 cells (36%). Only Daudi (Burkitt's lymphoma) cells were consistently more inhibited by interferon . In the other 24 human cells, the effect of interferon ß was greater or equal to interferon . Although no tissue specificity for interferon ß was evident, interferon generally had greater antiproliferative effects in cells of hematopoietic origin. The effect of interferon was usually established by 72 hr with little further growth inhibition at 120 hr. Conversely, interferon ß often had a greater antiproliferative effect at 120 than at 72 hr. These findings support the hypothesis that various interferons may differ in their biological, cell-regulatory, and clinical effects.

¹ Assisted by grants from the Veterans Administration and the American Cancer Society. Data presented in part at the Fifth International Congress of Virology, Strasbourg, France, August 1981 (4).

² To whom requests for reprints should be addressed.

Received 4/ 2/82. Accepted 8/19/82.

This article has been cited by other articles:

				R. Benjamin, A. Khwaja, N. Singh, J. McIntosh, A. Meager, M. Wadhwa, C. Streck, C. Ng, A. M. Davidoff, and A. C. Nathwani Continuous delivery of human type I interferons ({alpha}/{beta}) has significant activity against acute myeloid leukemia cells in vitro and in a xenograft model Blood, February 1, 2007; 109(3): 1244 - 1247. [Abstract] [Full Text] [PDF]

				Y. E. Chang, L. Pena, G. C. Sen, J. K. Park, and L. A. Laimins Long-Term Effect of Interferon on Keratinocytes That Maintain Human Papillomavirus Type 31 J. Virol., July 29, 2002; 76(17): 8864 - 8874. [Abstract] [Full Text] [PDF]

				M. Chawla-Sarkar, D. W. Leaman, B. S. Jacobs, and E. C. Borden IFN-{beta} Pretreatment Sensitizes Human Melanoma Cells to TRAIL/Apo2 Ligand-Induced Apoptosis J. Immunol., July 15, 2002; 169(2): 847 - 855. [Abstract] [Full Text] [PDF]

				M. Chawla-Sarkar, D. W. Leaman, and E. C. Borden Preferential Induction of Apoptosis by Interferon (IFN)-{beta} Compared with IFN-{{alpha}}2: Correlation with TRAIL/Apo2L Induction in Melanoma Cell Lines Clin. Cancer Res., June 1, 2001; 7(6): 1821 - 1831. [Abstract] [Full Text] [PDF]

				F. Ravandi, Z. Estrov, R. Kurzrock, J. B. Breitmeyer, B. J. Maschek, and M. Talpaz A Phase I Study of Recombinant Interferon-{{beta}} in Patients with Advanced Malignant Disease Clin. Cancer Res., December 1, 1999; 5(12): 3990 - 3998. [Abstract] [Full Text] [PDF]

				M. Lu and T. Shenk Human Cytomegalovirus UL69 Protein Induces Cells To Accumulate in G1 Phase of the Cell Cycle J. Virol., January 1, 1999; 73(1): 676 - 683. [Abstract] [Full Text] [PDF]

				S. Dhar, J. Gullbo, K. Nilsson, P. Nygren, and R. Larsson A Nonclonogenic Cytotoxicity Assay Using Primary Cultures of Patient Tumor Cells for Anticancer Drug Screening J Biomol Screen, April 1, 1998; 3(3): 207 - 216. [Abstract] [PDF]

				Q. Lin, C. Dong, and M. D. Cooper Impairment of  T and B Cell Development by Treatment with a Type I Interferon J. Exp. Med., January 5, 1998; 187(1): 79 - 87. [Abstract] [Full Text] [PDF]

				S. Wadler and E. L. Schwartz New Advances in Interferon Therapy of Cancer Oncologist, August 1, 1997; 2(4): 254 - 267. [Abstract] [Full Text] [PDF]